期刊文献+

酒石酸布托啡诺复合右美托咪定用于老年患者局麻下椎体成型术的临床观察

Clinical Observation of Butorphanol Combined Dexmedetomidine with in Vertebroplasty under Local Anesthesia in Elderly Patients
下载PDF
导出
摘要 目的:探讨酒石酸布托啡诺复合右美托咪定用于老年患者局麻下椎体成型术的安全性和有效性。方法:选择择期拟行经皮椎体成型术(percutaneous vertebroplasty,PVP)治疗的患者60例,随机分为右美托咪定+酒石酸布托啡诺组(DB组)及右美托咪定+生理盐水组(DS组),每组各30例。所有患者在局麻前予以右美托咪定静脉泵注(负荷剂量:0.5μg·kg^(-1),维持剂量:0.5μg·kg^(-1)·h^(-1))。局麻时给予DB组患者酒石酸布托啡诺15μg·kg^(-1)静脉注射,DS组患者则予以等量生理盐水。分别记录所有患者入室后5 min(T0)、改俯卧位时(T_(1))、套管针插入时(T_(2))、骨水泥注入时(T_(3))及术毕即刻(T_(4))的平均动脉压(mean artery pressure,MAP)、心率(heart rate,HR)、VAS及Ramsay评分;记录术中呼吸抑制、心动过缓等不良事件。结果:与DS组比较,T_(1)~T_(4)时DB组患者MAP明显更低,而T_(1)~T_(3)时DB组患者HR也更低(P<0.05);T_(2)~T_(3)时,DB组患者Ramsay评分显著低于DS组(P<0.05),而DB组患者VAS评分在T_(1)~T_(2)时明显低于DS组(P<0.05);两组间呼吸抑制、心动过缓等不良反应发生率比较无统计学差异(P>0.05)。结论:酒石酸布托啡诺复合右美托咪定有利于维持患者术中血流动力学稳定,降低患者术中疼痛评分,且不增加不良事件发生率。 Objective:To investigate the safety and efficacy of butorphanol combined with dexmedetomidine in vertebroplasty under local anesthesia in elderly patients.Methods:Sixty patients scheduled to undergo elective percutaneous vertebroplasty(PVP)were enrolled and randomly assigned into two groups,dexmedetomidine+butorphanol group(DB group,n=30)and dexmedetomidine+normal saline group(DS group,n=30).All patients received intravenous infusion of dexmedetomidine before operation(loading dose:0.5μg·kg^(-1),maintenance dose:0.5μg·kg^(-1)·h^(-1)).Simultaneously,patients in DB group were given intravenous injection of butorphanol 15μg·kg^(-1),while patients in DS group were given intravenous injection of the same volume of normal saline.The mean arterial pressure(MAP),heart rate(HR),VAS and Ramsay scores were recorded 5 min after entering the operation room(T0),at the time of changing of positon(T_(1)),trocar insertion(T_(2)),cement injection(T_(3))and the end of operation(T_(4)).The intraoperative adverse events were also recorded,such as respiratory depression and bradycardia.Results:Compared with DS group,the MAPs were lower at T_(1)~T_(4) and HRs were lower at T_(1)~T_(3)(P<0.05);the Ramsay score between DS group and DB group at T0~T_(4) were similar(P>0.05);however,the VAS scores in DB group were lower at T_(1)~T_(2) than that in DS group(P<0.05).There was no statistical difference existed when comparing the adverse events,such as respiratory depression and bradycardia,among two groups(P>0.05).Conclusion:Dexmedetomidine combined with butorphanol could be safely used in vertebroplasty under local anesthesia.It could help to maintain the hemodynamic stability,reduce pain intensity and did not increase the incidence of adverse events during surgery.
作者 刘号 凌建忠 张小琴 蔡红红 许波 LIU Hao;LING Jian-zhong;ZHANG Xiao-qin;CAI Hong-hong;XU Bo(Department of Anesthesiology,Yangzhou Hospital of Traditional Chinese Medicine,Yangzhou,225009,China;Department of Anesthesiology,Wuxi People’s Hospital,Wuxi,241023,China)
出处 《神经药理学报》 2020年第5期9-13,共5页 Acta Neuropharmacologica
关键词 酒石酸布托啡诺 右美托咪定 老年患者 椎体成型术 dexmedetomidine butorphanol elderly patients vertebroplasty
  • 相关文献

参考文献7

二级参考文献46

共引文献191

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部